Pipeline

Ifebemtinib

Ifebemtinib (also known as IN10018, ifebe, BI853520) is an orally administered, highly potent and selective small molecular inhibitor of the focal adhesion kinase (FAK). InxMed translational research has demonstrated the essential functions of FAK in tumor defense.

Learn more >>

OMTX705

OMTX705 is a potential first-in-class antibody-drug conjugate (ADC) targeting fibroblast activation protein (FAP) and carrying a novel tubulysin-based payload. It is designed to treat tumors characterized by FAP-expressing cancer-associated fibroblasts (CAFs), which play a key role in tumor microenvironment (TME) remodeling and therapy resistance.

Learn more >>

IN30758&IN30778

InxMed has developed ADC to address with aims of stronger, more potent ADC to overcome emerging resistance and companion biomarker test sparing.

Learn more >>